LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Exelixis Inc

Cerrado

SectorSanidad

42.99 1.63

Resumen

Variación precio

24h

Actual

Mínimo

42.27

Máximo

43

Métricas clave

By Trading Economics

Ingresos

20M

160M

Ventas

-11M

555M

P/B

Media del Sector

19.58

51.198

BPA

0.55

Margen de beneficios

28.736

Empleados

1,147

EBITDA

23M

194M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-1.56% downside

Dividendos

By Dow Jones

Próximas Ganancias

5 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.8B

12B

Apertura anterior

41.36

Cierre anterior

42.99

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

166 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Exelixis Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2025, 20:42 UTC

Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Nvidia, AMD, Super Micro, UnitedHealth, eToro, Oklo, Exelixis, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Exelixis Inc previsión

Precio Objetivo

By TipRanks

-1.56% descenso

Estimación a 12 Meses

Media 41.71 USD  -1.56%

Máximo 56 USD

Mínimo 29 USD

De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Exelixis Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

16 ratings

10

Comprar

6

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 36.6Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

166 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.